logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Außerordentliche Hauptversammlung 2023
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

RNA Immunomodulator

Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors


by Sovereign

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects


by Sovereign

Immunological effects of a novel RNA-based adjuvant in liver cancer patients


by Sovereign

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile


by Sovereign